Goldman Sachs’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,455
| Closed | -$54K | – | 5685 |
|
|
2022
Q1 | $54K | Buy |
1,455
+264
| +22% | +$9.8K | ﹤0.01% | 5452 |
|
|
2021
Q4 | $68K | Sell |
1,191
-6,047
| -84% | -$345K | ﹤0.01% | 5300 |
|
|
2021
Q3 | $740K | Buy |
7,238
+4,111
| +131% | +$420K | ﹤0.01% | 4162 |
|
|
2021
Q2 | $305K | Sell |
3,127
-528
| -14% | -$51.5K | ﹤0.01% | 4696 |
|
|
2021
Q1 | $373K | Buy |
+3,655
| New | +$373K | ﹤0.01% | 4528 |
|
|
2020
Q4 | – | Sell |
-1,653
| Closed | -$795K | – | 4631 |
|
|
2020
Q3 | $795K | Buy |
1,653
+304
| +23% | +$146K | ﹤0.01% | 3438 |
|
|
2020
Q2 | $1.05M | Buy |
1,349
+745
| +123% | +$578K | ﹤0.01% | 3193 |
|
|
2020
Q1 | $420K | Buy |
+604
| New | +$420K | ﹤0.01% | 3578 |
|